Date:	5/2/2022
Your Name:	T. Jake Samuel ]
Manuscript Title:	[Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients ]
Manuscript Number (if known):	157557-INS-CMED-RV-4

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	is
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]	-	t to the following statement to indicate your agreement to answered every question and have not altered the wo	

Date:	5/2/2022
Your Name:	Shenghan Lai
Manuscript Title:	[Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients ]
Manuscript Number (if known):	157557-INS-CMED-RV-4

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	se place an "X" nex	t to the following statement to indicate your agreeme	ent:
[oxtimes]	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.

Date:	5/2/2022
Your Name:	Michael Schär ]
Manuscript Title:	[Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients ]
Manuscript Number (if known):	157557-INS-CMED-RV-4

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		Employment (2005-2014), while some of the data presented in this study was acquired on equipment manufactured by Philips.  Click the tab key to add additional rows.
		Time frame: past 36 months	3
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None     ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]	-	e following statement to indicate your agreeme red every question and have not altered the wo	

Date:	5/2/2022
Your Name:	Katherine C. Wu, MD ]
Manuscript Title:	[Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients ]
Manuscript Number (if known):	157557-INS-CMED-RV-4

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIH grants HL103812 and HL132181	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational	None	
6	events  Payment for	Some Significant States Sign	
0	expert testimony	Notice	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		
[oxtimes]	☑ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:			5/2/2022			
Your Name:			Angela Steinberg			
Manuscript Title:			Myocardial ATP Depletion Detected Noning Failure Patients	[Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients ]		
Ma	nuscript Number (if k	nown):	157557-INS-CMED-RV-4			
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub		ipt. "Re of the m e in doul	lated" means any relation with for-profit or no anuscript. Disclosure represents a commitme	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.		
-	demiology of hyperted t medication is not me	-	•	acturers of antihypertensive medication, even if		
	tem #1 below, report me for disclosure is th		·	rithout time limit. For all other items, the time		
			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present		None			
1	present manuscript (e.g.,	Reyno		Funds paid to institution		
1	present manuscript (e.g., funding, provision of study materials,		None			
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Reyno	None	Funds paid to institution Funds paid to institution		
1	present manuscript (e.g., funding, provision of study materials,	Reyno	None	Funds paid to institution Funds paid to institution		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Reyno	None	Funds paid to institution Funds paid to institution		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Reyno	None	Funds paid to institution Funds paid to institution Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Reyno	None  Ilds Foundation	Funds paid to institution Funds paid to institution Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Reyno	None  Ilds Foundation  Time frame: past 36 month	Funds paid to institution Funds paid to institution Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Reyno	None  Ilds Foundation  Time frame: past 36 month	Funds paid to institution Funds paid to institution Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Reyno	None  Ilds Foundation  Time frame: past 36 month	Funds paid to institution Funds paid to institution Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Reyno NIH	None  Ilds Foundation  Time frame: past 36 month	Funds paid to institution Funds paid to institution Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Reyno NIH	None  Ilds Foundation  Time frame: past 36 month  None	Funds paid to institution Funds paid to institution Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Reyno NIH	None  Ilds Foundation  Time frame: past 36 month  None	Funds paid to institution Funds paid to institution Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None     Non	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	5/2/2022
Your Name:	_[An-Chi Wei ]
Manuscript Title:	ig[Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients $ig]$
Manuscript Number (if known):	157557-INS-CMED-RV-4

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	[ None [Grant MOST110-2636-B-002-017	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None □	
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	[⊠] None	
Plea	se place an "X" nex	t to the following statement to indicate your agreeme	nt:
[oxtimes]	☑ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	5/2/2022
Your Name:	Mark E. Anderson, MD, PhD
Manuscript Title:	Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients
Manuscript Number (if known):	157557-INS-CMED-RV-4

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			ties with whom you have this r indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	None None None	Time frame: past 36 month	Click the tab key to add additional rows.
	any entity (if not indicated in item #1 above).			
3	Royalties or licenses	None     Non		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None  None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None    Solution   Sol
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have	answered every question and have not altered the wo	ording of any of the questions on this form.

Date:	5/2/2022	
Your Name:	Gordon F. Tomaselli	
Manuscript Title:	Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients	
Manuscript Number (if known):	157557-INS-CMED-RV-4	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIH/NHLBI Donald W. Reynolds Foundation	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None	
6	Payment for expert testimony	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	[□] None	
8	Patents planned, issued or pending	□ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Amgen Inc Leducq Foundation	Scientific advisory board Scientific advisory board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:			5/2/2022		
Your Name:			[Gary Gerstenblith ]		
Manuscript Title:			[Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients ]		
Ma	nuscript Number (if k	nown):	157557-INS-CMED-RV-4		
content of your manuscript. "Rela affected by the content of the mai indicate a bias. If you are in doubt The author's relationships/activitie			ted" means any relation with for-profit or noncorrection. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For		
-	medication is not me	-	· · · · · · · · · · · · · · · · · · ·	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	em #1 below, report and for disclosure is the			vithout time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Cines the initial planning	6.0	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NHLBI	one  Is Foundation	Payment to Johns Hopkins School of Medicine Payment to Johns Hopkins School of Medicine Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	NHLBI	one	Payment to Johns Hopkins School of Medicine Payment to Johns Hopkins School of Medicine Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	NHLBI Reynold	ds Foundation	Payment to Johns Hopkins School of Medicine Payment to Johns Hopkins School of Medicine Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[□] None	
6	Payment for expert testimony	[□] None	
7	Support for attending meetings and/or travel	[□] None	
8	Patents planned, issued or pending	[□] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have	answered every question and have not altered the wo	ording of any of the questions on this form.

Date:	5/2/2022
Your Name:	Paul A. Bottomley
Manuscript Title:	[Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients ]
Manuscript Number (if known):	157557-INS-CMED-RV-4

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None  Russell H Morgan Professorship, Dept of Radiology	Funds held by Johns Hopkins University/Radiology  Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None  NIH HL61912 NIH HL056882 DW Reynolds Foundation	Supported work acquiring the MRS data Supported work acquiring the MRS data Supported studies and analysis
3	Royalties or licenses	None related to content of this manuscript	
4	Consulting fees	None related to content of this manuscript	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None  Newton Abraham Visiting Professor, Lincoln College, Oxford University UK	Sept 2018-Mar 2019
6	Payment for expert testimony	[⊠ None	


		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	None other than #5 above.	
8	Patents planned, issued or pending	None related to content of this manuscript	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None Since 2010: Magnetic Resonance in Medicine Magnetic Resonance Imaging MAGMA "Handbook of Magnetic Resonance Spectroscopy In Vivo", Wiley Press, 2016	Deputy Editor Editorial Board Editorial Board Editor
11	Stock or stock options	None related to content of this manuscript	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None related to content of this manuscript	
13	Other financial or non-financial interests	None related to content of this manuscript	
Plea	se place an "X" nex	t to the following statement to indicate your agreeme	nt:
	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.

	e:		5/2/2022		
Your Name: Manuscript Title:			Robert G Weiss Myocardial ATP Depletion Detected Noninvasively Predicts Sudden Cardiac Death Risk in Heart Failure Patients		
Ma	nuscript Number (if kı	nown):	157557-INS-CMED-RV-4		
content of your manuscript. "Rela affected by the content of the ma					
epi	·	ision, yo	•	example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
	tem #1 below, report a me for disclosure is the		The state of the s	rithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present	[_] N	one		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		al Institutes of Health ynolds Foundation	Payments made to Institution Payments made to institution Click the tab key to add additional rows.	
	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for			Payments made to institution  Click the tab key to add additional rows.	
2	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	DW Re	ynolds Foundation	Payments made to institution  Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None  None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None    Solution   Sol
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

# The Journal of Clinical Investigation



Click on boxes to check/uncheck items.

# Checklist for submitting a revised Clinical Medicine manuscript

In addition to addressing the items noted in the decision letter regarding your manuscript, ensure that your revised manuscript adheres to the guidelines below. For full submission details, visit the ICL website

JCI website.
Required files
Manuscript
PDF of a clean version of the entire manuscript; include references, figures, figure legends, and tables.
✓ PDF of a marked-up version of the entire manuscript showing revisions and beginning with a
point-by-point response to reviewer comments.  Word or RTF file of all manuscript text; include references, figure legends, tables, and table
legends (but not figures, images, markup, or point-by-point responses).
✓ Single PDF file of completed ICMJE uniform disclosure forms from all authors.
For clinical trials, a PDF of the appropriate reporting checklist (CONSORT, STROBE. etc.).
Figures
Publication-quality figures in TIFF format. See detailed instructions for figure preparation.
Recommended: Graphical abstract (details available here).
Supplemental material
✓ Supplemental information, figures, and modest-sized tables, as:
(a) (if applicable) a PDF in which reviewer-requested changes are highlighted
☑ (b) a clean, publication-quality PDF
Upload any supplemental videos and/or large spreadsheets separately.
☐ Before submission, carefully review all supplemental files; they will not be checked by a copy
editor. The Journal is not responsible for any errors contained in supplemental material.
Gels and blots
☐ For any figure showing a cropped blot or gel: a PDF, PPT, or PPTX file (distinct from any other
supplemental material) that shows the entire unedited image.
☐ Annotate each image as, e.g., "Full unedited gel for Figure 2B."
☐ Clearly indicate which bands were used for the figures.
_ clearly material realization and regards
Formatting and style
Recommended 9,000/maximum 12,000 words (including title page, full text, references, figure legends,
and tables).
☑ Double-spaced throughout, including references and tables; figure legends may be single spaced if
necessary to keep a figure and its legend on the same page.
☑ All pages are numbered.
☑ Each section begins on a new page.
Abbreviations and acronyms
Standard JCI abbreviations and acronyms are used without definition.
All other abbreviations and acronyms are spelled out at first use in the Abstract and again at first
use in the main text (with the abbreviated form appearing in parentheses) and used without
definition thereafter.
Gene names and symbols
☐ Gene names and symbols conform to official NCBI Gene Nomenclature. ☐ Presented according to  Cl Gene nomenclature and style.
Italicization
Generally reserved for gene symbols, genotypes, and species names.
☐ denerally reserved for gene symbols, genotypes, and species maries.  ☐ Terms such as in vivo. in vitro. etc are not italicized.

# Unpublished data, manuscripts in preparation or under review, and personal communications

- ☐ Cited parenthetically in the text, not as numbered references; e.g., "(Jane L. Doe, UCLA, Los Angeles, California, USA, unpublished observations)."
- ☐ Written permission to cite unpublished observations by individuals external to the author's research team (email is sufficient) is submitted.

#### **Reference citations**

- ☑ Appear in parentheses preceded by a space, e.g., "as described previously (1, 2)"; "several research groups (4–10) have found."
- ✓ No superscript, boldface, italics, etc.

#### Figure and table callouts

- Figures and tables are called out in numerical order.
- ☑ "Figure," "Table," "Supplemental Figure," "Supplemental Table," etc., are spelled out.
- ☑ Callouts appear in parentheses (no boldface or italics) preceded by a space, unless
  grammatically part of the sentence: "the levels increased (Figure 5A)"; "data shown in Table 2."
- ☑ Parts are called out as, e.g., "Figure 1A," "Figure 2, A and B," "Figure 3, B–D."

☑ Tit	ile page
☑ Ma	nuscript title
<b>✓</b> Clea	r, concise, and limited to 15 words, including conjunctions.
✓ Refe	rs to the relevant disease or disease model studied.
✓ No s	ubtitles, colons, periods, or nonstandard abbreviations.
<b>☑</b> Aut	hors and affiliations
_	or names are provided in full (for example, "Benita J. Sjögren") and in the appropriate order itles, honorifics, degrees, or certifications.
✓ Affil	ations correspond to the period when the work was performed.
	outhors whose affiliation has changed since completion of the work, specify the present iation and location below the numbered list.
✓ Affil	ation footnotes are assigned consecutively using superscripted numbers (1, 2, 3, etc.). ations include departments, institutions, city, state (if applicable), and country (but no ling addresses or zip/regional codes).
	esponding author's complete name, address, telephone number (including country code licable), and email address.
☐ Cons	ortium/study groups shown as authors (e.g., CARDIoGRAM Consortium)
	Jnless the members of the group appear as authors, each individual member and their affiliation are listed in the supplemental material, under the heading Supplemental Acknowledgments.
	he following sentence appears in Acknowledgments: "See Supplemental
	Acknowledgments for details on {name of consortium}."
<b>☑</b> Cor	flict-of-interest statement
	tement consistent with the Journal's conflict-of-interest policy is included; if no author has a lict, state the following: "The authors have declared that no conflict of interest exists."
	tents are involved, the patent or patent application number(s) are provided and the nes of the associated authors specified.

✓ Abstract	✓ Acknowledgments
✓ Structured format with the sections Background, Methods, Results, Conclusion, Trial	✓ States sources of support in the form of grants, equipment, or drugs.
registration, Funding.	✓ Grant numbers are provided as applicable.
✓ Maximum 250 words.	$\square$ Other acknowledgments, such as of colleagues for advice, are included as appropriate.
✓ No references.	
$\checkmark$ All nonstandard abbreviations are defined at first use.	✓ References
	✓ Prepared according to How to prepare references for submission.
Main text (presented in the following order)	
✓ Introduction	☑ Figure legends
	✓ Maximum 300 words.
☑ Results	☐ Each begins with a stand-alone title, irrespective of the individual parts.
☑ Discussion	✓ Figure parts are called out in boldface: (A), (B–D), (C and E).
✓ Methods	Symbols and abbreviations introduced in figures are defined and used consistently throughout.
✓ Demographic reporting (see details here)	✓ Use of terms within the legends is consistent with that in the figures themselves.
Reporting on race and ethnicity adheres to NIH guidelines or other applicable	☑ In each figure legend where appropriate, the statistical test(s) used are described.
authoritative standards.	✓ For each panel representing multiple experiments, the exact number of samples ( <i>n</i> ) is reported.
Descriptors for any demographic identities are clear, unbiased, and up-to-date.	For representative experiments, the number of times the experiment was conducted is reported.
☑ Data for any demographic variable are inclusive; if any information is unavailable or	✓ Error bars are defined either in Statistics or in the individual legends; e.g., "Data represent
incomplete, an explanation is provided.	mean ± SEM."
Specify whether the participants or investigators made the classifications; and whether the	✓ Variance around the mean and statistical analysis are not provided for figures representing
options were defined by the investigators or participants.	fewer than 3 independent samples.
Complete manufacturer name (omit location) is provided for each proprietary item used.	$\square$ For histological panels and insets, scale bars are defined or total original magnification is
For animal models, precise genotype, strain, number of backcrosses, sex, age, and source	specified in the legends.
are specifed.	
☐ Antibodies: Commercial — source and catalog/clone number are specified for each; custom —	☑ Figures
generation of antibodies is described (or an appropriate reference is cited).	Prepared according to How to prepare figures for submission.
Source of all cell lines used is indicated.	For clinical trials, the appropriate flow diagram appears as a figure.
☐ Data sets for gene expression microarrays, SNP arrays, and high-throughput sequencing studies	✓ Parts are labeled with capital letters: A, B, C, etc., with no designated subparts.
are deposited in a public repository, and accession number(s) provided in Methods in the main	☐ Graphs of quantitative data are presented as either dot plots, with average and appropriate
text (for publication, data must be publicly available).  Statistics	error bars indicated; or box-and-whisker plots, with values defined in the legend (bounds of
✓ Section appears near the end of Methods ( <u>before</u> "Study approval").	the boxes, lines within the boxes, whiskers, and any outlying values). Dynamite plunger plots
✓ The <i>P</i> value used to determine significance of differences is specified; e.g., "A <i>P</i> value less	are not permitted.
than 0.05 was considered significant."	☐ If lanes in a gel or blot image are spliced together into a composite image, the lanes are distinguished
✓ Analysis appropriately corrects for multiple comparisons (more than 2 groups) and for	with a thin vertical dividing line (black on a gray background; or white on a black background). State in
repeated measures (multiple measurements within subjects).	the legend that the lanes were run on the same gel but were noncontiguous.
☐ If samples were excluded, a statement describes inclusion/exclusion criteria.	
✓ Study approval	<b>☑ Tables</b>
✓ Stand-alone paragraph at the end of Methods.	✓ Prepared in Word table format (not pasted in from another application).
✓ Declaration of approval of human and/or animal studies, specifying the official name and	✓ Self-contained and self-explanatory.
location of the applicable institutional review board(s).	✓ Preceded by brief titles.
✓ For human studies, a statement indicates receipt of written informed consent from	✓ Each table fits on a single page and is presented on its own page.
participants and/or their parents/guardians.	✓ Callouts to footnotes (designated with superscript capital letters) are assigned alphabetically
☐ For use of photographs of participants, a separate statement of written informed consent is included.	row by row.
	✓ No subparts or subsections (for example, Table 1A and Table 1B).
✓ Author contributions	☑ Column headings in tables apply to all values throughout the column; a new row of column
	headings may not be introduced within a table.
Contribution of each author (identified by initials) is specified; e.g., designing research studies,	✓ See "Methods" above for reporting on demographics.
conducting experiments, acquiring data, analyzing data, providing reagents, writing the	
manuscript. Multiple contributions may be listed for a single individual, and more than one	
individual may be associated with a single contribution.  ☑ Grammatically complete sentences are used.	
🖭 Grammaticany complete sentences are used.	

among these authors is stated.

 $\hfill\square$  For manuscripts with 2 or more co–first authors, the method used to assign authorship order